国家一类抗高血压化学合成新药“博帝”(萘哌地尔),获得国家药品监督管理局颁发的新药证书和生产批件,5月18日起上市。该药由贵州益康制药有限公司历时8年独立研制开发完成,是我国首创的有自主知识产权的抗高血压化学合成新药。“博帝”是从苯基哌嗪衍生物中筛选出的新型 The country’s new anti-hypertensive chemical synthesis drug “Bodi” (Naftopidil) has received the new drug certificate and production approval issued by the State Drug Administration, and will be listed on May 18. The medicine was independently developed by Guizhou Yikang Pharmaceutical Co., Ltd., which lasted 8 years. It is China’s first antihypertensive chemical synthetic drug with independent intellectual property rights. “Bodi” is a new type of screening from phenylpiperazine derivatives